Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Hematology

What Happens If You Miss a TKI Dose for CML? Next Steps

At a Glance

If you miss a CML TKI dose, do not double up. Follow the instructions for your specific medicine; if unsure, skip the missed dose and take the next dose on schedule after contacting your oncology team or pharmacist. Repeated missed doses can reduce response and increase the risk of drug resistance.

If you accidentally forget to take your daily tyrosine kinase inhibitor (TKI) pill for Chronic Myeloid Leukemia (CML), the most important rule is never double up your next dose to make up for the missed one [1][2]. Taking two doses too close together can cause a dangerous spike of the drug in your body, significantly increasing the risk of severe side effects. Because different TKIs (such as imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib) have different dosing schedules and fasting requirements, there is no universal rule for when it is safe to take a late pill [3]. Always check the specific pharmacy leaflet for your exact medication. If you cannot find the instructions or are unsure, the safest approach is to skip the missed dose, resume your normal schedule with the next dose, and contact your oncology team or pharmacist [1].

Please be reassured that an isolated missed dose is a common human error and will not instantly ruin your treatment. However, consistently missing doses drops the drug levels in your blood over time, which increases the risk that your leukemia will develop drug resistance and stop responding to therapy [4][5].

What to Do If You Missed a Dose Today

When dealing with a missed dose, consistency and safety are your top priorities. Follow these steps:

  • Do not double up: Your prescribed dose is carefully calculated to effectively fight the leukemia while keeping side effects manageable [6]. Doubling a dose bypasses this safety balance and can lead to serious toxicity.
  • If you already double-dosed: If you accidentally took a double dose, or took your dose at the wrong time, contact your oncology team, oncology pharmacist, or local poison control center immediately for guidance. Seek emergency medical care if you experience severe symptoms like trouble breathing, fainting, chest pain, or significant bleeding [7].
  • Check your specific medication: Each CML TKI is processed differently by your body. For example, a twice-daily drug with strict fasting rules like nilotinib has much stricter missed-dose guidelines than a once-daily drug like imatinib [3]. Look at your official medication leaflet for the exact cutoff time for a missed dose, or call your pharmacist.
  • If you vomit after taking your pill: Do not automatically take another pill, as some of the drug may have already been absorbed into your system. Note the time you took the pill and the time you vomited, and contact your care team to ask if a replacement dose is necessary.

Why Strict Adherence Matters

To understand why taking your pill every day is critical, it helps to understand how TKIs work. TKIs are generally taken long-term to suppress the abnormal BCR-ABL1 protein (the “leukemia signal” that tells the cancer cells to multiply). While they are highly effective at controlling CML, most patients need continuous therapy, though some carefully selected patients with a deep, sustained response may eventually attempt a carefully supervised treatment-free remission [8].

Your doctor monitors your progress using a BCR-ABL1 PCR test, a highly sensitive blood test that measures exactly how much of this leukemia signal remains in your body (your molecular response) [9].

When you skip doses or take unplanned “holidays” from your medication, the level of the TKI in your bloodstream drops. While one missed dose won’t cause immediate harm, repeated dips in medication coverage allow the leukemia cells to multiply [10]. Over time, these multiplying cells can develop drug resistance, meaning they figure out how to survive even when you take the TKI again [4]. Studies consistently show that poor medication adherence is directly tied to a poorer molecular response and a higher risk of the leukemia progressing to a more dangerous phase [5][11].

What to Do If You Keep Missing Doses

If you find yourself missing doses frequently, it is important to identify the root cause so you and your care team can fix it. Do not feel ashamed—many patients struggle with adherence at some point, and your team is there to help [12].

  • If side effects are the problem: Are you skipping doses because the medication makes you feel sick, fatigued, or gives you diarrhea? Never suffer in silence or secretly stop taking your medication. Your doctor can often adjust your dose, prescribe supportive therapies to manage side effects, or even switch you to a different TKI while closely monitoring your molecular response [13][6].
  • If remembering is the problem: Consider using pill organizers or setting daily phone alarms. Make sure any reminders fit with your medication’s specific food or fasting requirements.
  • If cost or access is the problem: Avoid rationing your pills. Plan ahead for weekends, travel, or insurance delays so you do not run out. If cost is a barrier, let your oncology pharmacist or social worker know; they can often connect you with financial assistance programs or grants to help cover the cost [12][3].

Common questions in this guide

What should I do if I miss a dose of my CML TKI?
Do not take two doses together. Missed-dose instructions vary by TKI and dosing schedule, so check the medication leaflet or contact your oncology team or pharmacist; if you cannot confirm the instructions, skip the missed dose and resume your normal schedule with the next dose.
Will one missed CML TKI dose ruin my treatment?
A single missed dose is a common error and usually does not immediately undo treatment. Repeated missed doses can lower drug levels, make treatment work less well, and increase the risk of drug resistance. Tell your care team if missed doses are becoming frequent.
What if I accidentally take two CML TKI doses?
Contact your oncology team, oncology pharmacist, or local poison control center immediately for instructions. Seek emergency medical care if you have trouble breathing, fainting, chest pain, or significant bleeding.
Should I take another pill if I vomit after taking my CML TKI?
Do not automatically take a replacement dose because some medicine may already have been absorbed. Write down when you took the pill and when you vomited, then ask your care team whether another dose is needed.
How can I stop missing my CML medication?
Tell your doctor rather than stopping or skipping doses secretly. Your team may adjust the dose, prescribe medicines to control side effects, or switch you to another TKI while monitoring your blood-test response. Pill organizers, phone alarms, and financial or refill assistance can help with practical barriers.
Can missing CML TKI doses cause drug resistance?
Repeated missed doses can reduce TKI coverage and allow leukemia cells to multiply, which may contribute to drug resistance and a poorer treatment response. One isolated missed dose is not expected to cause immediate resistance, but frequent interruptions should be discussed with your care team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the exact missed-dose instructions for my specific TKI and dosing schedule?
  2. 2.If I vomit shortly after taking my pill, what is your protocol for whether I should take a replacement dose?
  3. 3.How do my recent BCR-ABL1 PCR tests look, and is there any sign that my medication adherence is affecting my molecular response?
  4. 4.Are there any dose adjustments or supportive medications we can try if side effects are making it hard for me to take my pill every day?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    The role of bosutinib in the treatment of chronic myeloid leukemia.

    Gambacorti-Passerini C, le Coutre P, Piazza R

    Future oncology (London, England) 2020; (16(2)):4395-4408 doi:10.2217/fon-2019-0555.

    PMID: 31833784
  2. 2

    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

    Saglio G, Jabbour E

    Leukemia & lymphoma 2018; (59(7)):1523-1538 doi:10.1080/10428194.2017.1379074.

    PMID: 28972424
  3. 3

    Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.

    Reff MJ, Shillingburg A, Shah B, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(1)):156-174 doi:10.1177/1078155219864640.

    PMID: 31354102
  4. 4

    Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

    Berman E, Jhanwar S, Hedvat C, et al.

    Leukemia research 2016; (49()):108-12.

    PMID: 27658269
  5. 5

    Chronic Myeloid Leukemia: A Review.

    Jabbour E, Kantarjian H

    JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

    PMID: 40094679
  6. 6

    Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms.

    Haddad FG, Kantarjian H

    Blood cancer journal 2026; (16(1)).

    PMID: 42209462
  7. 7

    Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib.

    Maruta S, Usami K, Tajiri K, et al.

    Cardio-oncology (London, England) 2021; (7(1)):31 doi:10.1186/s40959-021-00119-6.

    PMID: 34452646
  8. 8

    Optimizing patient selection for treatment-free remission.

    Rausch CR, Paul S

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(5)):1220-1224 doi:10.1177/1078155220925167.

    PMID: 32437235
  9. 9

    Molecular monitoring in CML: how deep? How often? How should it influence therapy?

    Shanmuganathan N, Hughes TP

    Blood 2018; (132(20)):2125-2133 doi:10.1182/blood-2018-05-848630.

    PMID: 30429156
  10. 10

    Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

    Soverini S, Bavaro L, De Benedittis C, et al.

    Blood 2020; (135(8)):534-541 doi:10.1182/blood.2019002969.

    PMID: 31877211
  11. 11

    Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.

    Geelen IGP, Thielen N, Janssen JJWM, et al.

    Haematologica 2017; (102(11)):1842-1849 doi:10.3324/haematol.2017.174953.

    PMID: 28860339
  12. 12

    Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.

    Alves R, Gonçalves AC, Rutella S, et al.

    Cancers 2021; (13(19)) doi:10.3390/cancers13194820.

    PMID: 34638304
  13. 13

    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.

    Cortes JE, Apperley JF, DeAngelo DJ, et al.

    Journal of hematology & oncology 2018; (11(1)):143 doi:10.1186/s13045-018-0685-2.

    PMID: 30587215

This page provides general information about missed CML TKI doses for educational purposes and does not constitute medical advice. Follow the instructions for your specific medicine and contact your oncology team or pharmacist with questions.

Get notified when new evidence is published on Chronic myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.